<DOC>
	<DOCNO>NCT01887600</DOCNO>
	<brief_summary>This study conduct treat anemia patient chronic kidney disease . Anemia reduce number red blood cell hemoglobin . Hemoglobin important transport oxygen blood . The purpose study see Roxadustat effective safe treatment anemia patient chronic kidney disease .</brief_summary>
	<brief_title>Roxadustat Treatment Anemia Chronic Kidney Disease Patients Not Requiring Dialysis</brief_title>
	<detailed_description>The study consist three study period follow : - Screening period : 6 week . - Treatment period : 52 104 week . - Post-Treatment Follow-Up period : 4 week</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion criterion : Subject diagnosis chronic kidney disease , Kidney Disease Outcomes Quality Initiative ( KDOQI ) Stage 3 , 4 5 , receive dialysis ; Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60 mL/min/1.73 m^2 estimate use abbreviated 4variable Modification Diet Renal Disease ( MDRD ) equation . The mean subject 's three recent Hb value Screening period , obtain least 4 day apart , must less equal 10.0 g/dL , difference less equal 1.0 g/dL high low value . The last Hb value must within 10 day prior randomization . Subject ferritin level great equal 30 ng/mL ( great equal 67.4 pmol/L ) screening . Subject transferrin saturation ( TSAT ) level great equal 5 % screening . Subject serum folate level great equal low limit normal screening . Subject serum vitamin B12 level great equal low limit normal screening . Subject 's alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) level less equal 3 x upper limit normal ( ULN ) , total bilirubin ( TBL ) less equal 1.5 x ULN . Subject 's body weight 45.0 kg maximum 160.0 kg . Exclusion criterion : Subject receive ESA treatment within 12 week prior randomization . Subject one dose IV iron within 12 week prior randomization . Subject receive RBC transfusion within 8 week prior randomization . Subject known history myelodysplastic syndrome multiple myeloma . Subject know hereditary hematologic disease thalassemia sickle cell anemia , pure red cell aplasia , know cause anemia CKD . Subject known hemosiderosis , hemochromatosis , coagulation disorder , hypercoagulable condition . Subject chronic inflammatory disease could impact erythropoiesis ( e.g. , systemic lupus erythematosus , rheumatoid arthritis , celiac disease ) even currently remission . Subject anticipated elective surgery expect lead significant blood loss anticipate elective coronary revascularization . Subject active chronic gastrointestinal bleeding . Subject receive prior treatment roxadustat hypoxiainducible factor Prolyl Hydroxylase Inhibitor ( HIFPHI ) . Subject treat ironchelating agent within 4 week prior randomization . Subject history chronic liver disease ( e.g. , cirrhosis fibrosis liver ) Subject know New York Heart Association Class III Intravenous ( IV ) congestive heart failure . Subject myocardial infarction , acute coronary syndrome , stroke , seizure , thrombotic/thromboembolic event ( e.g. , pulmonary embolism ) within 12 week prior randomization . Uncontrolled hypertension two blood pressure ( BP ) value systolic BP ( SBP ) great equal 160 mmHg diastolic BP ( DBP ) great equal 95 mmHg confirm repeat measurement within 2 week prior randomization . Subject diagnosis suspicion ( e.g. , complex kidney cyst Bosniak Category 2F high ) renal cell carcinoma renal ultrasound within 12 week prior randomization . Subject history malignancy , except follow : cancer determine cured remission great equal 5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp . Subject positive following : Human Immunodeficiency Virus ( HIV ) ; hepatitis B surface antigen ( HBsAg ) ; antihepatitis C virus antibody ( antiHCV Ab ) . Subject active clinically significant infection manifest White Blood Count ( WBC ) &gt; ULN , and/or fever , conjunction clinical sign symptom infection within one week prior randomization . Subject know untreated proliferative diabetic retinopathy , diabetic macular edema , macular degeneration retinal vein occlusion . Subject prior organ transplant ( explanted ) schedule organ transplantation . Subject participate interventional clinical study treat investigational drug within 30 day 5 half life limit set national law , whichever longer , prior initiation Screening . Subject anticipate use dapsone dose amount chronic use acetaminophen ( paracetamol ) &gt; 2.0 g/day treatment followup period study . Subject history alcohol drug abuse within 2 year prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease ( CKD )</keyword>
	<keyword>Hemoglobin ( Hb )</keyword>
	<keyword>non-dialysis</keyword>
</DOC>